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Colon carcinoma is one of the most common malignant tumours and the second 
cause of cancer-related deaths in developed countries.  
The objective of the research was to investigate the p53 expression in colorectal 
cancer and compare the expression levels of p53 with the macroscopic appearance and 
manner of growth of the tumours, followed by detection and identification of the 
expression levels of p53 as an important prognostic factor of the further course, 
outcome and data for the selection of appropriate therapy. 
Research was implemented as a prospective, clinical and experimental study. We 
used a postoperative material obtained by resection of colorectal cancer from 63 
patients of both sexes.  
The results showed that the majority of tumours 36/63, i.e. 57.1% were manifested 
as infiltrative forms, 9/63, i.e. 14.3% as ulcerating form, and 18/63, i.e. 28.6% of 
tumours had a polypoid – exophytic form.  
The results have shown that three tumours of infiltrative forms were p53 negative 
and 17 of them were p53 positive. In tumours with ulcerating form, eight were p53 
negative, and 16 of them were no p53 positive tumours. In vegetative tumour forms, 
four were p53 negative, and 15 of the were p53 positive. 
Positive p53 status was present in 52.4% of tumours. Expression of p53 was absent 
in 47.6% of the tumours and does not correlate with the macroscopic appearance and 
manner of tumour growth. Expression levels of p53 do not have a diagnostic, predictive 
and prognostic potential, while its importance is undeniable in the understanding of 
oncogenesis. Acta Medica Medianae 2011; 50(3):22-26. 
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Introduction 
 
Colon carcinoma is one of the most common 
malignant tumour and the second cause of 
cancer-related deaths in developed countries (1). 
Processes of division, differentiation and 
cell death are strictly controlled, and a disorder in 
the regulation of any of them gives rise to clones 
of cells that independently and inappropriately 
breed and produce the tumour mass. The onset 
of tumour is a complex process involving many 
genetic and molecular mechanisms. Oncogenesis 
is the result of accumulation of disorder in the 
structure and function of genes regulating cell 
proliferation mechanisms, reparation of DNA 
molecule or programmed cell death. These genes 
are: oncogenes, tumour suppressor genes, genes 
that are the matrix for the synthesis of the 
reparatory system enzymes, as well as genes 
that control apoptosis (2).  
The main role of tumour suppressor genes 
is to stop the cell cycle in order to repair defects 
in the structure of DNA molecule (3). Mutation 
and inactivation of tumour suppressor genes 
results in uncontrolled cell division and blockage 
of programmed cell death-apoptosis. They are 
inherited recessively and their expression occurs 
after inactivation of both alleles.  
p53 is the most common mutated gene in 
cancers, localized on chromosome 17, encodes 
p53 transcription factor that regulates cell cycle 
through the activation of genes transcription that 
stops the cycle in the G1 phase (when the gene 
is damaged) and activates apoptosis under 
certain conditions (4-6). Genes activated by p53 
transcription factor are WAF1 (cell cycle control), 
MDM2 (inhibits expression of p53), GADD45 (DNA 
repair control), Bax (apoptosis control) cyclin G, 
while inhibiting myc and bcl-2.  
The basic functions of p53 are participation 
in the reparation of DNA molecules (correcting 
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errors in the duplication of genetic material) as 
well as controlling the cell cycle, proliferation and 
differentiation. Also, when it comes to the accumu-
lation of genetic errors, p53 allows apoptosis, which 
is why it is known as „guardian of the cell genome”. 
The data obtained as a result of various 
clinical and basic studies suggest that damage or 
mutation of p53 leads to gene amplification of 
p53 and loss of control of cell cycle and apoptosis. 
The level of these changes has reflected the 
degree of unfavourable prognosis in patients, the 
very reason that tumours with over-expression of 
p53 have shown resistance to radiation and most 
chemotherapeutics (7). 
The objective of this study was to determine 
the possible correlation between the morphological 
parameters and the expression levels of p53 and 
identification of possible prognostic significance of 
this correlation. In accordance with the basic 
objective, the following specific tasks have been 
set:  
1.  Examination of p53 expression at the 
operational material-resectioned segments 
from patients with colorectal carcinoma.  
2.  Correlation between p53 expression with 
the macroscopic appearance and manner of 
tumour growth. 
3.  Detection and identification of p53 tumour 
suppressor gene expression levels as an 
important prognostic factor for further progress 
and outcome of disease and the data for the 
choice of suitable, optimal, target, individual 
anti-tumour therapy. 
 
Materials and methods 
 
The study was implemented as a prospective, 
clinical and experimental study. We used a 
postoperative material obtained by resection of the 
colorectal tumours of 63 patients of both sexes, 
from the Surgery Clinic of Clinical Centre in 
Kragujevac. In order to obtain as much relevant 
histopathological data, the routine haematoxylin - 
eosin (HE) and immunohistochemical methods were 
performed at the Centre for Pathological-Anatomical 
Diagnosis of Clinical Centre “Kragujevac” in Kragujevac. 
Routine HE method was used for patho-
histological verification of tumours, and histo-
pathological analysis. In the routine processing of 
products, tissue samples were fixed in 4% 
neutral buffer formalin solution, in 24 hours, at 
room temperature. Upon completion of fixation, 
they were dehydrated through a series of 
alcohols of increasing concentration (70%, 96% 
and 100%), stained in xylol and embedded in 
paraffin. Tissue sections, 4 µm thick, were cut 
with microtomes Leica SM 2000R and Leica 
Reinhart Austria.   
After deparaffinization in xylol and hydration in 
decreasing order of alcohol, sections were stained 
with haematoxylin according to Mayer, stained in 
2% eosin, then dehydrated, stained and mounted 
on a plate with Canada balsam (8-10). 
Immunohistochemical methods were used 
to identify the expression of antigen in colorectal 
cancer resection sample. The procedure for immuno-
histochemical staining included the unmasking of 
antigens, blocking of endogenous peroxidase, 
incubation with primary antiserum preparation and 
the procedure of immuno-histochemical methods - 
LSAB+ - HRP (11).  
For detection of p53 murine monoclonal 
antibody was applied (DAKO p53 DO-7 monoclonal 
mouse clone, 1:200) and highly sensitive specific 
streptavidin - biotin immunohistochemical method 
(LSAB+/HRP, DAKO, Denmark), in which the 
streptavidin is labelled with peroxidase and as a 
chromogen 1,3 – diaminobenzidine was used . As 
a general solvent of antiserum and rinsing 
solution between the different steps in the 
immunohistochemical staining procedure 0.1 M 
phosphate buffer pH 7.4 was used. Cell nuclei 
were stained with Mayer's haematoxylin. 
Cut off is the selected threshold value to 
distinguish positive and negative expression of 
p53. Cut off in this study to assess positivity was 
> 30% (score of overexpression if more than 
30% tumour cells showed immunoreactivity for 
p53). Scoring system is based on determination 
of the percentage of immunoreactive nuclei of 
tumour cells as well as the intensity of immuno-
reactive staining. Adding points for the percentage 
of immunoreactivity and intensity gives the total, 
maximum possible points for the evaluation of 
expression (Table 1).  
 
Table 1. Total possible maximum points for the assessment 
of expression 
 
% IMMUNOREACTIVE 
NUCLEI 
INTENSITY OF 
IMMUNOREACTIVE 
STAINING 
0 = <5% stained nuclei  0 = no nuclei stained 
1 = 5 do 30% stained 
nuclei 
1 = poor intensity of nuclei 
staining 
2 = 30 do 50% stained 
nuclei 
2 = moderate intensity of 
nuclei staining 
3 = 50 do 70% stained 
nuclei 
3 = very intensive staining 
4 = 70 do 90% stained 
nuclei 
 
5 > 90% stained nuclei   
 
Immunohistochemical staining was carried 
out with the control of quality and specifics of 
staining, using positive and negative controls 
according to the propositions of UK NEQAS (UK 
National External Quality Assessment for immuno-
cytochemistry). For statistical data processing 
SPSS software package and methods of descriptive 
statistics were used (frequencies, percentages, 
median, and percentiles). Testing according to 
two descriptive variables was carried out using 
Chi-square test and Fisher test. Investigation of Correlation of tumour suppressor gene p53 expression with the...                                                                Dušica Petrović et al. 
the effect of several variables on a binary 
variable was performed using binary logistic 
regression multivariant analysis. 
 
Results 
 
Nuclear expression of p53 was present in 
33/63, i.e. in 52.4% (grade of positivity for more 
than 30% tumour cells showing immunoreactivity 
for p53). In 30/63 i.e. 47.6% had no expression of 
p53  (Table 2). 
 
Table 2. Expression of p53 
 
P53 expression  Frequency  Percentage (%) 
Negative 33  52,4 
Positive 30  47,6 
Total 63  100,0 
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The largest number of tumours 36/63, i.e. 
57.1% was manifested in the form of infiltrative 
forms, 9/63, i.e. 14.3% as ulcerating form, and 
18/63, i.e. 28.6% of tumours had a polypoid - 
exophytic appearance (Table 3). 
 
Table 3. Macroscopic manifestation of tumour 
 
Macroscopic 
manifestation of 
tumour 
Frequency 
Percentage 
(%) 
Exophytic 18  28,6 
Ulcerating 9  14,3 
Infiltration 36  57,1 
Total 63  100,0 
 
The results show that three tumours of 
infiltrative forms were p53 negative and 17 of them 
were p53 positive. In tumours with ulcerating form, 
eight were p53 negative, and 16 of them were no 
p53  positive tumours. In vegetative tumour forms, 
four tumours were p53 negative, and 15 of the 
were p53 positive (Table 4). 
 
Table 4. Correlation of macroscopic manifestation and 
expression of p53 
 
Macroscopic 
manifestation of 
tumour 
P53- P53+ 
Percentage 
(%) - 
Percentage 
(%) + 
Vegetative form  4  15  21.05  78.95 
Ulcerating form  8  16  33.33  66.67 
Infiltrative form  3  17  15  85 
 
Macroscopic manifestation of the tumour and 
p53 are independent (p=0.104). 
In order to obtain reliable parameters to 
examine the various factors that could affect the 
expression of p53, binary logistic regression was 
performed.  
The presented results showed that p53 is not 
dependent on clinical and histological parameters 
(Figure 1-4). 
 
 
Figure 1. p53 - the internal negative control (IHH, x 100) 
 
 
 
Figure 2. Tumour cells nuclei show no immunoreactivity to 
r53 (IHH, x 100) 
 
 
 
Figure 3. Tumour cells nuclei showed immunoreactivity of 
p53 to 30% (IHH, x 200) 
 
 
 
Figure 4. Tumour cells nuclei showed immunoreactivity 
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Discussion 
 
Colorectal cancer (CRC) is one of the most 
common causes of morbidity and mortality in 
both western world and our region. Classifications 
and established prognostic parameters, which are 
today used in the treatment of CRC, still only 
partially provide information about the course and 
outcome of this disease, hence there is a need to 
improve existing and identify new diagnostic and 
prognostic markers. In this regard it is especially 
important to identify molecular markers that 
would provide insight into the potential behaviour 
or aggressiveness of the tumour (12-14). 
Since the current clinical and morphologic 
parameters (histological type of tumour, degree 
of differentiation, tumour stage, nodal status, 
invasion of vascular structures and surgical 
margins) still retain their dominant role in 
diagnostic procedures, molecular profiling would 
complement them, mostly in terms of recognizing 
the response to the therapy (genetic changes), or 
in terms of application in improving the screening 
of high-risk categories to allow for timely and 
successful treatment  (15). 
The largest number of tumours 36/63, i.e. 
57.1% was manifested in the form of infiltrations, 
9 / 63, i.e. 14.3% as ulcerating form, and 18/63, 
i.e. 28.6% of tumours had a polypoid – exophytic 
look.  
The results of this study showed that 
nuclear expression of p53 was present in 33 
cases or 52.4% of the total, with a rating of 
positivity evaluated as p53 expression in more 
than 30% of tumour cells. In 30 samples, or 
47.6% of the total number of analyzed CRC there 
was no p53expression. The data are consistent 
with data from the literature on the expression of 
p53 markers in colorectal cancer, according to 
which the normal p53 expression in all carcinomas 
is 45-70%, while the expression of this marker in 
colorectal carcinomas is 42-67% (16, 17).  
The results of various studies suggest that, 
in regards to prognosis, it is not sufficient to 
follow only the expression of p53, but it is 
necessary to monitor the expression of other 
tumour markers, whose behaviour can also lead 
to better therapeutic approaches for the treatment 
of malignant tumours (18-21). 
P53 expression does not depend on the 
macroscopic manifestations of tumours and tumour 
growth pattern, i.e., there is no correlation between 
p53 expression and the macroscopic manifestation 
and manner of growth of CRC, which would serve 
as a prognostic factor in the further course and 
outcome of the illness. 
Although the influence of macroscopic 
manifestation of the tumour on the p53 expression 
was not statistically significant (p=0.124), it was 
found that in ulcerating forms the possibility that 
p53 is positive is many times lower (odds ratio 
0,032, p=0,017). 
 
Conclusion  
 
Expression of p53 was present in 52, 5% of 
the tumours and does not correlate with the 
macroscopic manifestation or the growth pattern of 
colorectal carcinoma.  
Based on the aforesaid, it could be concluded 
that in previous studies the role of p53 as an 
important prognostic indicator has not been proven. 
Evaluation of the genes and molecular profiling can 
help identify groups of patients with overexpression 
of p53, which might imply a particular therapeutic 
intervention and an important therapeutic target for 
screening purposes.  
Expression level of p53 does not have 
diagnostic, predictive and prognostic potentials, 
while its importance is undeniable in the under-
standing of oncogenesis. 
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KORELACIJA EKSPRESIJE P53 TUMOR SUPRESOR GENA SA 
MAKROSKOPSKOM MANIFESTACIJOM I NAČINOM RASTA 
KOLOREKTALNIH KARCINOMA 
 
Dušica Petrović, Vesna Stanković, Miloš Milosavljević i Vladimir Bulatović 
 
  Karcinom debelog creva jedan je od najčešćih malignih tumora i drugi po redu 
uzročnik smrti od karcinoma u razvijenim zemljama. 
Cilj istraživanja bio je ispitivanje ekspresije p53  kod kolorektalnog karcinoma kao i 
komparacija nivoa ekspresije p53 sa makroskopskim izgledom i načinom rasta tumora, 
zatim detekcija i identifikacija nivoa ekspresije p53 kao značajnog prognostičkog faktora 
daljeg toka,  ishoda bolesti i podatka za izbor adekvatne terapije. 
Istraživanje je urađeno kao prospektivna, kliničko-eksperimentalna studija. Korišćen 
je postoperativni materijal dobijen resekcijom kolorektalnog karcinoma od 63 bolesnika 
oba pola.  
Dobijeni rezultati su pokazali da se najveći broj tumora, 36/63, tj. 57.1%, 
manifestovao u vidu infiltrativne forme, 9/63, tj. 14.3% kao ulcerišuća forma, a 18/63, 
tj. 28.6% tumora imalo je polipoidni – egzofitičan izgled.  
Rezultati su pokazali da je tri tumora infiltrativne forme bilo p53 negativno a 17 ih 
je bilo p53 pozitivno. Kod tumora ulcerišuće forme 8 je bilo p53 negativno, a 16 je bilo 
pozitivnih p53 tumora. Kod tumora vegetativne forme, četiri je bilo p53 negativno, a 15 
tumora  bilo je p53 pozitivno. 
Pozitivan p53 status bio je u 52,4% tumora. Ekspresija p53 izostala je u 47,6% 
tumora i ne korelira sa patohistološkim karakteristikama tumora. Nivo ekspresije p53 
nema dijagnostički, prediktivni i prognostički potencijal, dok je neosporna njegova 
važnost u razumevanju onkogeneze. Acta Medica Medianae 2011;50(3):22-26. 
 
Ključne reči: kolorektalni karcinom, p53, korelacija, makroskopski izgled, način rasta 